Creatinyl amino acids-new hybrid compounds with neuroprotective activity

Journal of Peptide Science

Volumn 17, Issue 9, 2011, Pages 620-626

  Burov, Sergey ^a   Leko, Maria ^a   Dorosh, Marina ^a   Dobrodumov, Anatoliy ^a   Veselkina, Olga ^b  

^a INSTITUTE OF MACROMOLECULAR COMPOUNDS   (Russian Federation)

^b Closed Joint Stock Company Vertex   (Russian Federation)

Author keywords

Brain stroke; Creatine p toluenesulfonate; Creatinyl amino acids; Neuroprotective activity; Sarcosine guanidinylation

Indexed keywords

AMINO ACID; CREATININE; CREATINYL AMINO ACID; FORMIC ACID DERIVATIVE; TOLUENESULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; CYCLIZATION; DISSOLUTION; DRUG ACTIVITY; DRUG DEGRADATION; DRUG STABILITY; DRUG SYNTHESIS; HYPOXIA; LARGE SCALE PRODUCTION; LIFESPAN; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; STROKE;

AMINO ACIDS; ANIMALS; BLOOD-BRAIN BARRIER; CREATINE; MALE; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; STROKE;

ANIMALIA;

EID: 79961172469     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1379     Document Type: Article

References (24)

1. Christie DL. Functional insights into the creatine transporter. Subcell. Biochem. 2007; 46: 99-118.
2. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 1999; 5: 347-350.
3. Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. 1998; 18: 156-163.
4. Zhu S, Li M, Figueroa BE, Liu A, Stavrovskaya IG, Pasinelli P, Beal MF, Brown RH Jr, Kristal BS, Ferrante RJ, Friedlander RM. Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J. Neurosci. 2004; 24: 5909-5912.
5. Klein AM, Ferrante RJ, In Creatine and Creatine Kinase in Health and Disease. Subcellular Biochemistry, Vol. 46, Salomons GS, Wyss M (eds.)Dordrecht: Springer: 2007; 205-243.
6. Kristensen CA, Askenasy N, Jain RK, Koretsky AP. Creatine and cyclocreatine treatment of human colon adenocarcinoma xenografts: 31P and 1H magnetic resonance spectroscopic studies. Br. J. Cancer 1999; DOI 10.1038/sj.bjc.6690045.
7. Vennerstrom JL, Miller DW. Creatine ester pronutrient compounds and formulations. WO/2002/022135. March 21, 2002.
8. Lunardi G, Parodi A, Perasso L, Pohvozcheva AV, Scarrone S, Adriano E, Florio T, Gandolfo C, Cupello A, Burov SV, Balestrino M. The creatine transporter mediates the uptake of creatine by brain tissue, but not the uptake of two creatine-derived compounds. Neuroscience 2006; DOI 10.1016/j.neuroscience.2006.06.058.
9. Giese MW, Lecher CS. Qualitative in vitro NMR analysis of creatine ethyl ester pronutrient in human plasma. Int. J. Sports Med. 2009; DOI 10.1055/s-0029-1231045.
10. Giese MW, Lecher CS. Non-enzymatic cyclization of creatine ethyl ester to creatinine. Biochem. Biophys. Res. Commun. 2009; DOI 10.1016/j.bbrc.2009.07.151.
11. Hofmann E, Wünsch A. Verwendung von Nitroprussidreagenz in der Papierchromatographie. Naturzuissenschaften 1958; 45: 338.
12. Gibson GE, Peterson C, Sansone J. Decreases in amino acids and acetylcholine metabolism during hypoxia. J. Neurochem. 1981; 37: 192-201.
13. Koizumi J, Yoshida Y, Nakazawa T, Ooneda G. Experimental studies of ischemic brain edema. I: a new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn. J. Stroke 1986; 8: 1-8.
14. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91.
15. Belayev L, Busto R, Zhao W, Fernandez G, Ginsberg MD. Middle cerebral artery occlusion in the mouse by intraluminal suture coated with poly-L-lysine: neurological and histological validation. Brain Res. 1999; DOI 10.1016/S0006-8993(99)01528-0.
16. Li F, Irie K, Anwer MS, Fisher M. Delayed thiphenyltatrazolium chloride staining remains useful for evaluatting cerebral infarct volume in a rat stroke model. J. Cereb. Blood Flow Metab. 1997; 17: 1132-1135.
17. Burov SV, Khromov AN. Creatine amides, a method for the production thereof and an agent exhibiting a neuroprotective action. Russian Patent 2354645, November 21, 2007.
18. Weiss S, Krommer H. Process for the preparation of creatine or creatine-monohydrate. European Patent 0754679, July 18, 1995.
19. An L, Zheng Y, Zhang G. Process for producing creatine or creatine monohydrate. Chinese Patent 99118985, September 7, 1999.
20. Musiol H-J, Moroder L. N, N'-di-tert-butoxycarbonyl-1H-benzotriazole-1-carboxamidine derivatives are highly reactive guanidinylating reagents. Org. Lett. 2001; DOI 10.1021/ol010191q.
21. Katritzky AR, Parris RL, Allin SM, Steel PJ. Benzotriazole-1-carboxamidinium tosylate: an alternative method for the conversion of amines to guanidines. Synth. Commun. 1995; 25: 1173-186.
22. Criado M, Aguilar JS, de Robertis E. The use of p-toluene sulfonate to dissolve synaptosomal membrane proteins into organic solvents. Anal. Biochem. 1980; 103: 289-294.
23. Andrushchenko VV, Vogel HJ, Prenner EJ. Optimization of the hydrochloric acid concentration used for trifluoroacetate removal from synthetic peptides. J. Pept. Sci. 2007; DOI 10.1002/psc.793.
24. Prass K, Royl G, Lindauer U, Freyer D, Megow D, Dirnagl U, Stöckler-Ipsiroglu G, Wallimann T, Priller J. Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. J. Cereb. Blood Flow Metab. 2007; DOI 10.1038/sj.jcbfm.9600351.